Feasibility and strategy analysis of radiotherapy consolidation following immunotherapy for stage IV esophageal squamous cell carcinoma - Takeaways - MDSpire

Feasibility and strategy analysis of radiotherapy consolidation following immunotherapy for stage IV esophageal squamous cell carcinoma

  • By

  • Hao Su

  • Xinyu Zhao

  • Xiaoyu Qin

  • Xu Zhou

  • Mianli Li

  • Lijun Tian

  • June 19, 2026

  • 0 min

Share

  • 1

    Esophageal squamous cell carcinoma (ESCC) accounts for approximately 85% of esophageal cancer cases among Chinese patients.

  • 2

    Immunotherapy combined with chemotherapy has improved survival rates for stage IV ESCC, but local control remains a challenge.

  • 3

    Preclinical studies indicate a synergistic effect between radiotherapy and immunotherapy in enhancing local lesion control.

  • 4

    Clinical trials show that consolidation radiotherapy can significantly prolong survival in patients with stage IV ESCC.

  • 5

    The review explores the feasibility and implementation strategies for radiotherapy following immunotherapy in stage IV ESCC patients.

Original Source(s)

Feasibility and strategy analysis of radiotherapy consolidation following immunotherapy for stage IV esophageal squamous cell carcinoma

  • by Hao Su, Xinyu Zhao, Xiaoyu Qin, Xu Zhou, Mianli Li, Lijun Tian

  • June 19, 2026

Related Content

A deep learning-based radiomic nomogram derived from visceral fat for early prediction of gastrointestinal stromal tumor risk grade

The regulatory roles of dysregulated lactate dehydrogenase A in anti-tumor immunity within immune cells

Location of AI risk markers and associated mammographic features in screening mammograms obtained years before screen-detected breast cancer